


Healthcare | Large Cap
Cipla Ltd. demonstrates a strong overall financial profile, characterized by outstanding profitability and an exceptionally stable, low-debt structure. The company's ability to generate profit from its sales and assets is a significant strength. Its reliance on owner's funds rather than borrowed money indicates a very low-risk financial position, providing a solid foundation for its operations. However, a key area of concern is the company's operational efficiency. It faces challenges in quickly converting inventory into sales and collecting payments from customers. While growth has been impressive in recent years, financial projections indicate a potential slowdown and even a decline in profits, which represents a notable future risk. Despite this, the company's capacity to cover its interest payments and dividends remains excellent, underscoring its financial stability.
Cipla Ltd. demonstrates a strong overall financial profile, characterized by outstanding profitability and an exceptionally stable, low-debt structure. The company's ability to generate profit from its sales and assets is a significant strength. Its reliance on owner's funds rather than borrowed money indicates a very low-risk financial position, providing a solid foundation for its operations. However, a key area of concern is the company's operational efficiency. It faces challenges in quickly converting inventory into sales and collecting payments from customers. While growth has been impressive in recent years, financial projections indicate a potential slowdown and even a decline in profits, which represents a notable future risk. Despite this, the company's capacity to cover its interest payments and dividends remains excellent, underscoring its financial stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
33.94
Industry Median
30.92
Large Cap Median
33.43
P/E RATIO
30.76
P/B RATIO
3.47
Industry Median
3.39
Large Cap Median
5.23
P/S RATIO
4.24
Industry Median
3.36
Large Cap Median
5.63
Others
PEG RATIO
2.67
EV/EBITDA RATIO
18.26
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1477 as on Aug 6, 2026.
The company's growth profile is strong but shows signs of future volatility. It has demonstrated excellent growth in revenue, earnings per share, and its asset base in recent years. This points to successful expansion and market performance. However, a significant negative projection for operating profit and net income growth in the near future is a major concern. This suggests that while the company has been expanding, its profitability from this growth is expected to decline sharply, posing a risk to future shareholder returns.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 13.59 | 4.55 | 13.28 | 6.88 | 2.23 |
| Operating Profit Growth Rate | 7.08 | 10.41 | 25.14 | 13.3 | -17.47 |
| Earnings Per Share (EPS) Growth | 4.59 | 11.29 | 47.08 | 27.87 | -26.44 |
| Asset Growth Rate | 8.05 | 9.1 | 11.03 | 14.76 | 13.83 |
| Net Income Growth Rate | 6.61 | 11.23 | 46.63 | 26.84 | -26.7 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 38.14 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Alkem Laboratories Ltd | 8.08 | 29.08 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 3 | Divis Laboratories Ltd | 7.91 | 86.31 | Highly Overvalued | 3441.00 | 98.20 | 2568.00 |
| 4 | Lupin Ltd | 7.84 | 20.45 | Neutral | 8816.00 | 139.24 | 5355.00 |
| 5 | Cipla Ltd | 7.62 | 30.76 | Neutral | 5883.00 | 43.51 | 3862.00 |
| 6 | Mankind Pharma Ltd | 7.61 | 52.23 | Overvalued | 3617.00 | 49.34 | 1938.00 |
| 7 | Zydus Lifesciences Ltd | 7.60 | 22.12 | Neutral | 8475.00 | 35.69 | 5124.00 |
| 8 | Laurus Labs Ltd | 7.10 | 111.18 | Neutral | 1778.00 | 13.71 | 890.00 |
| 9 | Dr Reddys Laboratories Ltd | 6.68 | 23.29 | Neutral | 6454.00 | 38.57 | 4158.00 |
| 10 | Glenmark Pharmaceuticals Ltd | 6.36 | 47.04 | Neutral | 4572.00 | -7.12 | 1362.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Quarterly Report⬤23rd Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
Concall Report⬤30th Oct 25
Q2 FY26 Earnings Conference Call
BULLISH SENTIMENT